The company provides comprehensive tumor profiling services using next-generation sequencing and multiplex molecular testing, coupled with bioinformatics tools, curated proprietary databases and data visualization technologies. Their services range from cancer prevention, early detection, treatment selection, and disease monitoring. They offer genomic assays that provide insights to biomarker discovery and patient stratification for clinical trials. ACT Genomics combines experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, cancer monitoring, risk assessment, and immunotherapy evaluation. They are dedicated to turning every cancer patient's genetic information into actionable resolutions.